Stratasys has entered an agreement with CollPlant Biotechnologies to jointly develop and commercialise a solution for the industrial-scale bioprinting of tissues and organs.
The companies will initially collaborate on the development of a bioprinting solution for regenerative breast implants produced by CollPlant.
CollPlant CEO Yehiel Tal said: “The P3 technology allows printing with high resolution and process control, and we believe that the combined, pioneering technologies of both companies will streamline the development and production process so that we have the most efficient means to produce our regenerative breast implants and other potential tissues and organs.”
The partnership will leverage CollPlant’s rh-Collagen-based bio-inks and Stratasys’ P3 3D printing technology-based bioprinter to develop a solution to bio-fabricate human tissues and organs.
The new bioprinter will be used to produce CollPlant’s advanced breast implants, which will promote natural breast tissue regeneration without eliciting an adverse immune response in humans.
CollPlant’s breast implants are expected to serve as a potentially safer and more natural alternative for both aesthetic and reconstructive procedures.
The agreement will also enable both entities to cross-promote each other’s bioprinting products.
Customers can receive Stratasys’ bioprinter along with CollPlant’s bio-inks, while CollPlant’s business partners and customers will be offered Stratasys’ bioprinter.
Stratasys CEO Dr Yoav Zeif said: “This agreement is well-aligned with our strategy to deliver complete solutions for high-growth industry applications with our ecosystem of partners, and the production scale and precision 3D printing capabilities of Stratasys’ P3 Programmable Photopolymerization technology are a particularly strong fit for bioprinting applications.”
In January this year, CollPlant concluded a large-animal trial for its 3D bioprinted regenerative breast implants. Reduced-size 3D bioprinted implants were implanted in a porcine animal model, as part of the preclinical study.
The objectives of the study were fully achieved, without any signs of adverse reactions. The study showed progressive stages of tissue regeneration after three months.